Erratum: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature (PLoS ONE (2013) 8:1 (e54193) DOI: 10.1371/journal.pone.0054193);Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Barr, Martin P ^a   Gray, Steven G ^a   Hoffmann, Andreas C ^b   Hilger, Ralf A ^b   Thomale, Juergen ^c   O'Flaherty, John D ^a   Fennell, Dean A ^d   Richard, Derek ^e   O'Leary, John J ^f   O'Byrne, Kenneth J ^a  

^a Dublin Molecular Medicine Centre   (Ireland)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^f ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; CISPLATIN; DNA; HERMES ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CISPLATIN-RESISTANT NON SMALL CELL LUNG CANCER; CLONOGENIC ASSAY; DNA ADDUCT; DNA DAMAGE; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; PHENOTYPE; PLURIPOTENT STEM CELL; TREATMENT RESPONSE;

EID: 84872530707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0233739     Document Type: Erratum

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Prestayko AW, D'Aoust JC, Issell BF, Crooke ST, (1979) Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 6: 17-39.
3. Kelland LR, (2000) Preclinical perspectives on platinum resistance. Drugs 59(suppl 4): 37-38.
4. Bunn PA Jr, Kelly K, (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100.
5. Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, et al. (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133-2141.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
7. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, et al. (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106: 16281-16286.
8. Crawford N, Chacko AD, Savage KI, McCoy F, Redmond K, et al. (2011) Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis 16: 311-320.
9. Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA, (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 52: 5674-5680.
10. Patnaik SK, Kannisto E, Mallick R, Yendamuri S, (2011) Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One 6: e22379.
11. Wang J, Wang H, Zhao L, Fan S, Yang Z, et al. (2010) Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res 30: 3593-3598.
12. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C, (2006) Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319.
13. Liedert B, Pluim D, Schellens J, Thomale J, (2006) Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 34: e47.
14. Ozols RF (1991) Ovarian cancer: new clinical approaches. Cancer Treat Rev 18 (suppl A): 77-83.
15. Giaccone G, (2000) Clinical perspectives on platinum resistance. Drugs 59(suppl 4): 9-17.
16. Ozols RF, (1992) Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 6: 879-894.
17. Gore ME, Fryatt I, Wiltshaw E, Dawson T, Robinson BA, et al. (1989) Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 60: 767-769.
18. Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S, et al. (1990) Carboplatin: Current Perspectives and Future Directions. In: Bunn P, Canetta R, Ozols R, Rozencweig M, editors. WB Saunders Company: Philadelphia, 133.
19. Agarwal ML, Agarwal A, Taylor WR, Stark GR, (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 92: 8493-8497.
20. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
21. Sekiguchi I, Suzuki M, Tamada T, Shinomiya N, Tsuru S, et al. (1996) Effects of cisplatin on cell cycle kinetics, morphological change, and cleavage pattern of DNA in two human ovarian carcinoma cell lines. Oncology 53: 19-26.
22. Sorenson CM, Barry MA, Eastman A, (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755.
23. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R, (1996) Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 50: 1536-1540.
24. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514.
25. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, et al. (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3: 2637.
26. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, et al. (2009) The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36: 446-453.
27. Alexander CM, Puchalski J, Klos KS, Badders N, Ailles L, et al. (2009) Separating stem cells by flow cytometry: reducing variability for solid tissues. Cell Stem Cell 5: 579-583.
28. Wu Y, Wu PY, (2009) CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 18: 1127-1134.
29. Du L, Wang H, He L, Zhang J, Ni B, et al. (2008) CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14: 6751-6760.
30. Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, et al. (2007) Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One 2: 243.
31. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, et al. (2010) Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 5: 14062.
32. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, et al. (2010) Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28: 649-660.
33. Moreb J, Schweder M, Suresh A, Zucali JR, (1996) Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 3: 24-30.
34. Sreerama L, Sladek NE, (1997) Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. Adv Exp Med Biol 414: 81-94.
35. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, et al. (2009) Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330-338.
36. Sullivan JP, Minna JD, Shay JW, (2010) Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 29: 61-72.
37. Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, et al. (2007) Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9: 625-635.
38. Chen S, Xu Y, Chen Y, Li X, Mou W, et al. (2012) SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS One 7: e36326.
39. Boulikas T, Vougiouka M, (2003) Cisplatin and platinum drugs at the molecular level. Oncol Rep 10: 1663-1682.
40. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, et al. (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62: 4899-4902.
41. McDonald ES, Randon KR, Knight A, Windebank AJ, (2005) Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 18: 305-313.
42. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H, (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121: 172-176.
43. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, et al. (2000) Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85: 777-781.
44. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM, (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868.
45. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, et al. (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565.
46. Samimi G, Katano K, Holzer AK, Safaei R, Howell SB, (2004) Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66: 25-32.